Use of Most Bothersome Symptom as a Co-Primary Endpoint in an Acute Treatment of Migraine Trial

被引：0
|
作者：
Dodick, David W. [1 ]
Tepper, Stewart J. [2 ]
Friedaman, Deborah [3 ]
Gelfand, Amy [4 ]
Cowan, Robert P. [5 ]
Schmidt, Pete [5 ]
Engels, Jean [6 ]
Rapoport, Alan [7 ]
Kellerman, Donald J. [8 ]
机构：
[1] Mayo Clin, Scottsdale, AZ USA
[2] Dartmouth Hitchcock, Hanover, NH USA
[3] UT Southwestern, Dallas, TX USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Stanford Univ, Palo Alto, CA 94304 USA
[6] Engels Consulting, Minneapolis, MN USA
[7] David Geffen Sch Med, Los Angeles, CA USA
[8] Zosano Pharma, Fremont, CA USA
来源：
CEPHALALGIA | 2017年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PO-02-171
引用
收藏
页码：361 / 362
页数：2
相关论文
共 50 条
  • [31] Most Bothersome Symptom' is not independently associated to response to PPI treatment in patients from general practice
    Meineche-Schmidt, V
    GASTROENTEROLOGY, 2003, 124 (04) : A224 - A224
  • [32] Patient Global Impression of Change Related to Improvement in Most Bothersome Symptom Following Treatment With Eptinezumab
    Cady, Roger
    McGill, Lora
    Hirman, Joe
    Biondi, David
    Lipton, Richard
    NEUROLOGY, 2019, 92 (15)
  • [33] Patient-reported symptom distress, and most bothersome issues, before and during cancer treatment
    Hong, Fangxin
    Blonquist, Traci M.
    Halpenny, Barbara
    Berry, Donna L.
    PATIENT-RELATED OUTCOME MEASURES, 2016, 7 : 127 - 135
  • [34] Patient-identified most bothersome symptom as a driver of health-related quality of life experienced by patients with migraine
    Jonsson, Linus
    Awad, Susanne F.
    Regnier, Stephane A.
    Talon, Brian
    Kymes, Steven
    Lee, Xin Ying
    Goadsby, Peter J.
    NEUROLOGY, 2023, 100 (17)
  • [35] Patient Global Impression of Change Related to Improvement in Most Bothersome Symptom Following Treatment With Eptinezumab
    Lipton, Richard B.
    McGill, Lora
    Hirman, Joe
    Biondi, David
    Cady, Roger
    CEPHALALGIA, 2019, 39 : 233 - 234
  • [36] Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology
    Fiteni, Frederic
    Pam, Alhousseiny
    Anota, Amelie
    Vernerey, Dewi
    Paget-Bailly, Sophie
    Westeel, Virginie
    Bonnetain, Franck
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (08) : 885 - 891
  • [37] THE MOST BOTHERSOME SYMPTOM IN FUNCTIONAL BOWEL DISORDERS INFLUENCES USE OF MEDICATION, QUALITY OF LIFE AND HEALTH CARE TILIZATION
    Simren, Magnus
    Whitehead, William E.
    Sperber, Ami D.
    Tornblom, Hans
    Palsson, Olafur S.
    GASTROENTEROLOGY, 2019, 156 (06) : S464 - S464
  • [38] Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention
    Lipton, Richard B.
    Goadsby, Peter J.
    Dodick, David W.
    McGinley, James S.
    Houts, Carrie R.
    Wirth, R. J.
    Kymes, Steve
    Ettrup, Anders
    Osterberg, Ole
    Cady, Roger
    Ashina, Messoud
    Buse, Dawn C.
    HEADACHE, 2022, 62 (06): : 690 - 699
  • [39] Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine
    Sandrini, G
    Dahlöf, CG
    Mathew, N
    Nappi, G
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (11) : 1356 - 1365
  • [40] Interim monitoring in a treatment strategy trial with a composite primary endpoint
    Kang, Minhee
    Grund, Birgit
    Hunsberger, Sally
    Glidden, David
    Volberding, Paul
    CONTEMPORARY CLINICAL TRIALS, 2019, 86
12345